Alex Bataller retweetledi

🔑 KEY FINDING: 52% of patients showed immunophenotypic shifts after revumenib — often myeloid/stem-like → monocytic/myelomonocytic. Among MRD+ patients in remission, 67% had antigen expression changes vs. pre-treatment AML! 👇
@AlexBataller

English
























